Alzheimer’s drug aducanumab not approved for use in EUon December 17, 2021 at 12:19 pm

- Advertisement -
- Advertisement -
- Advertisement -
- Advertisement -

Charities are disappointed but regulators say there is still little evidence of the drug’s benefit.

Brain scan

Image source, Getty Images

The European Medicines Agency has said no to approving a new drug for Alzheimer’s disease in the EU.

Aducanumab does not appear to be effective at treating adults with early-stage symptoms, the EMA said.

Alzheimer’s charities say they are disappointed by the decision because thousands of people are left with no treatment options.

The drug – the first new treatment for 20 years – was controversially approved in the US in June.

At the time, many scientists said there was little evidence from trials of it being of benefit despite it targeting amyloid – a protein that forms abnormal clumps in the brains of people with Alzheimer’s.

Biogen, the manufacturer of the drug, can ask for the EMA’s decision to be re-examined within the next two weeks.

It’s not known whether the company will submit a separate application for approval to the UK regulator, the MHRA.

- Advertisement -

Discover

Sponsor

Latest

In a U-turn, US surgeon general asks CDC to see if face masks can prevent coronavirus spread after all

KEY POINTS U.S. Surgeon General Jerome Adams had initially advised against the general public wearing face masks. However, Adams told NBC’s “TODAY” show on...

War in Ukraine: Change of emphasis or admission of failure by Moscow?on March 25, 2022 at 8:18 pm

Moscow now says the main aim is to "liberate" eastern Ukraine - a change of emphasis or more?

Ryan Reynolds speaks Welsh during awards acceptanceon November 15, 2022 at 8:28 pm

Ryan Reynolds and Rob McElhenney have been given an award by S4C for promoting Wales.Ryan Reynolds spoke Welsh as he and Rob McElhenney accepted...

Coronavirus and markets: Cramer and four others on what to watch next

Wall Street is watching for positive signs as states and cities begin to reopen from Covid-19 lockdowns. Five market experts weigh in. Jim Cramer, host of CNBC’s “Mad...

Vanessa Bryant testifies she was ‘blindsided’ by leaked photoson August 19, 2022 at 9:25 pm

Vanessa Bryant is seeking millions for emotional distress over photos taken at the accident site.Vanessa Bryant is seeking millions for emotional distress over photos...